drugset / Trial / NCT02388048
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
A clinical study to evaluate a treatment with two drugs, named Ofatumumab and Ibrutinib, in patients with lymphoblastic acute leukemia who have been already treated with other therapies.
Timeline
- Start
- 2015-10
- Primary completion
- 2024-04-03
- Completion
- 2024-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 420 mg | Oral |
| Subject | Ofatumumab | Monoclonal antibody | 2000 mg | — |